YORK (Reuters Health) May 23 –
Guidant Corp. said on Thursday that preliminary results of a single-blinded clinical study comparing the company’s Achieve paclitaxel-coated stent to a bare metal stent showed similar adverse cardiac event rates.
Specifically, after 30 days, one treatment arm had a 1.2% major adverse cardiac event (MACE) rate, while the other had a 0.4% MACE rate. Because the study is still blinded, it is
not known which group received the paclitaxel-coated stent.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!